VolitionRX Ltd VNRX 深 滬
等待開盤 02-03 09:30:00 美东时间
0.2645
-0.020
-7.19%
華盛通- 最 高0.2943
- 今 開0.29
- 成交量 174.51万股
- 最 低 0.2623
- 昨 收 0.285
- 總市值 3253.35万
- 52周最高 0.94
- 市盈率 靜 --
- 換手率 1.42%
- 52周最低 0.22
- 委 比 0.00%
- 總股本 1.23亿
- 歷史最高 9.28
- 量 比 0.77
- 振 幅 11.23%
- 歷史最低 0.22
- 每 手 1
- 風險率 0.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多VolitionRx Unveils Study Supporting Nu.Q NETs Blood Test for Hidradenitis Suppurativa Management
VolitionRx Unveils Study Supporting Nu.Q NETs Blood Test for Hidradenitis Suppurativa Management VolitionRx Limited has announced the results of a new clinical study demonstrating the use of its Nu.Q® NETs assay in patient management for Hidradenitis Suppurativa (HS), a chronic disease affecting app
01-28 01:25
VolitionRX Ltd. Announces Date for Upcoming Special Meeting of Stockholders
VolitionRX Ltd. Announces Date for Upcoming Special Meeting of Stockholders VolitionRx Limited will hold a Special Meeting of Stockholders on March 31, 2026, at 93-95 Gloucester Place, London, United Kingdom. The board of directors has circulated proxy materials for the meeting, and all proposals an
01-27 06:20
Volition Continues to Extend Access to Nu.Q® Vet Cancer Test
HENDERSON, Nev., Jan. 20, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of two new centralized l...
01-20 21:25
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers INVO Fertility (NASDAQ:IVF) shares increased by 345.6% to $3.62 during...
01-20 20:05
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
D. Boral Capital Maintains Buy on VolitionRX, Maintains $3 Price Target
D. Boral Capital analyst Jason Kolbert maintains VolitionRX (AMEX:VNRX) with a Buy and maintains $3 price target.
01-09 20:05
VolitionRx Secures $2M Via Senior Secured Convertible Note And Warrants For ~7M Shares At $0.5714/Share
VolitionRx Limited (NYSE:VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into an amended and restated securities purchase agreement (the "Amended
01-08 22:17
VolitionRx Secures $2.0 Million in Funding
HENDERSON, Nev., Jan. 8, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entere...
01-08 22:15
VolitionRx Announces Results From Clinical Study Demonstrating High Accuracy Of Nu.Q Vet Feline Assay In Detecting Lymphoma In Cats
Paves the Way for World's First Feline Liquid Biopsy Test for Cancer DetectionHENDERSON, Nev., Jan. 8, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces
01-08 21:47
VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats
Paves the Way for World's First Feline Liquid Biopsy Test for Cancer Detection HENDERSON, Nev., Jan. 8, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-na...
01-08 21:45
